New drug aims to calm immune attack on kidneys
NCT ID NCT06209177
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a drug called ARO-CFB in 49 healthy volunteers and people with IgA nephropathy, a kidney disease where the immune system damages the kidneys. The main goal was to check safety and how the drug moves through the body. Participants received either one or two doses of the drug or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ARO-CFB
- What this could lead to
- If it works, this could point toward a new treatment for IgA nephropathy by targeting a part of the immune system that damages kidneys.
- What could go wrong
- This is a very early phase 1/2a trial with only 49 participants, so safety and dosing are still being figured out. It may not lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Auckland, 1010, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Immune cell therapy takes on kidney disease
- Steroids for kidney disease: do they prevent failure Long-Term?